Skip to content
You are now leaving https://www.ionispharma.com to visit

Positive clinical data at AAN 2019 reinforces Ionis’ commitment to delivering life-changing medicines to patients with neurological diseases

Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington’s disease, ALS, prion disease and others Updates on RG6042 (IONIS-HTTRx) and tofersen (IONIS-SOD1Rx), two of at least four antisense medicines entering Phase 3 studies in 2019 Webcast to discuss neurological